反相色谱 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-09. Numbers and descriptions here follow the published literature rather than marketing material.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
The discovery of the new elements and the new data on neutron capture were initially kept secret on the orders of the US military until 1955 due to Cold War tensions. Nevertheless, the Berkeley team were able to prepare einsteinium and fermium by civilian means, through the neutron bombardment of plutonium-239, and published this work in 1954 with the disclaimer that it was not the first studies that had been carried out on those elements. The "Ivy Mike" studies were declassified and published in 1955. The first significant (submicrogram) amounts of einsteinium were produced in 1961 by Cunningham and colleagues, but this has not been done for fermium yet. The first isotope of mendelevium, 256Md (half-life 87 min), was synthesized by Albert Ghiorso, Glenn T. Seaborg, Gregory Robert Choppin, Bernard G. Harvey and Stanley Gerald Thompson when they bombarded an 253Es target with alpha particles in the 60-inch cyclotron of Berkeley Radiation Laboratory; this was the first isotope of any element to be synthesized one atom at a time. There were several attempts to obtain isotopes of nobelium by Swedish (1957) and American (1958) groups, but the first reliable result was the synthesis of 256No by the Russian group of Georgy Flyorov in 1965, as acknowledged by the IUPAC in 1992. In their experiments, Flyorov et al. bombarded uranium-238 with neon-22. In 1961, Ghiorso et al. obtained the first isotope of lawrencium by irradiating californium (mostly californium-252) with boron-10 and boron-11 ions.
Several previous attempts have been made to create glucose-responsive insulin, with varying degrees of success. In the 2010s, Eli Lilly and Company developed an experimental basal insulin analogue called peglispro (BIL), which showed a prolonged and flat activity profile with hepato-preferential action. Although BIL demonstrated improved glycemic control, reduced nocturnal hypoglycemia, and less weight gain compared to insulin glargine, it was associated with increased liver fat, triglycerides, and liver enzyme levels. Due to these concerns and the uncertain regulatory pathway, Lilly discontinued the development of BIL in 2015. Other experimental analogues that are in development include LAPS Insulin115, an ultralong analogue being researched by Hanmi Pharm, and two basal oral analogues in development by Novo Nordisk, OI338 and OI320.
Only when the South Ossetians opened up with artillery on Georgian villages, did the offensive to take Tskhinvali begin." The cable also says, "All evidence available to the country team supports Saakashvili's statement that this fight was not Georgia's original intention. Key Georgian officials, who would have had responsibility for an attack on South Ossetia have been on leave, and the Georgians only began mobilizing August 7 once the attack was well underway." The cable reported, "Fighting had continued throughout the night of August 7, resuming four hours after President Saakashvili unilaterally declared a cease-fire at 1900." The cable noted, "Although most in the Georgian government believed that the fighting had started as a ploy of de facto leader Kokoity, Saakashvili was now concerned that this might have been a Russian pretext and a further attack could be expected." The cable also reported that "The Georgians believe the South Ossetians are targeting the Russians to provoke a bigger Georgian-Russian conflict" and named the person responsible for the escalation of the conflict, "One plausible explanation for all this is that de facto leader Kokoity decided to roll the dice and stimulate a conflict with the Georgians in hopes of bringing in the Russians and thereby saving himself or enhancing his position." The cable reported that Russia had launched 4 ballistic missiles against Tskhinvali. The cable reported that the Georgians were fighting with unidentified Russian combatants north of Tskhinvali.
Sources: en.wikipedia.org
SF Holding Co., Limited is a Chinese multinational integrated logistics service provider headquartered in Shenzhen, Guangdong offering a wide range of services, including express, freight, cold chain logistics, Intra-city on-demand delivery, supply chains, and international logistics. Its business covers 339 prefecture-level cities across China and operates in over 200 countries. It operates 99 cargo aircraft and over 200,000 vehicles, making it the largest air and land transport fleet in Asia. It owns SF Airlines the largest cargo airline in China. SF Holding's business model includes direct operations, integrated capabilities, and third-party independence. It is listed on Shenzhen Stock Exchange and is included in the CSI 300 and MSCI Emerging Markets Index constituents. It has four listed companies: KLN, SF Intra-city, SF REIT and KEX Express (Thailand). In 2023, it recorded a net profit of RMB 8.2 billion.
=== Nanotechnology === The Culture has highly advanced nanotechnology, though descriptions of such technology in the books is limited. Many of the described uses are by or for Special Circumstances, but there are no indications that the use of nanotechnology is limited in any way. (In a passage in one of the books, there is a brief reference to the question of sentience when comparing the human brain or a "pico-level substrate".) One of the primary clandestine uses of nanotechnology is information gathering. The Culture likes to be in the know, and as described in Matter "they tend to know everything." Aside from its vast network of sympathetic allies and wandering Culture citizens one of the primary ways that the Culture keeps track of important events is by the use of practically invisible nanobots capable of recording and transmitting their observations. This technique is described as especially useful to track potentially dangerous people (such as ex-Special Circumstances agents). Via such nanotechnology, it is potentially possible for the Culture (or similarly advanced societies) to see everything happening on a given planet, orbital or any other habitat. The usage of such devices is limited by various treaties and agreements among the Involved. In addition, EDust assassins are potent Culture terror weapons, composed entirely of nano machines called EDust, or "Everything Dust." They are capable of taking almost any shape or form, including swarms of insects or entire humans or aliens, and possess powerful weaponry capable of levelling entire buildings.
== Research and career == Whilst Wolk enjoyed her career at the Geisinger Health System, she discovered that she was being paid considerably less than her male colleagues. She was told this wage disparity would only be rectified if she returned to college and completed a postgraduate degree, so she joined Wilkes University. Wolk returned to Geisinger, where she led the clinical microbiology laboratory for fourteen years. Wolk returned to university in the mid-nineties to work toward a doctorate at the University of Arizona. She studied medical parasitology, demonstrating that chlorine could be used as an effective water treatment of Encephalitozoon syn. Septata intestinalis. She also demonstrated that spectrophotometric methods could be used for laboratory-based disinfection studies. After earning her doctorate, Wolk moved to the Mayo Clinic, where she completed a fellowship in clinical microbiology. During her fellowship, she developed a polymerase chain reaction (PCR) assay that could detect Encephalitozoon intestinalis in stool samples. Her rapid testing systems were translated out of the research lab, and used for the diagnostics of bacteria in emergency departments. After completing her fellowship, Wolk returned to Arizona, where she was made Director of the Southern Arizona VA Health Care System. There she expanded the programs in clinical microbiology, and established the Infectious Diseases Research Core (IDRC), a Clinical Laboratory Improvement Amendments (CLIA) compliant research laboratory to test novel infectious diseases.
Sources: en.wikipedia.org
Bethlem myopathy is a slowly progressive muscle disease characterized predominantly by contractures, rigidity of the spine, skin abnormalities and proximal muscle weakness. Symptoms may present as early as infancy, with typical contractures and hyperlaxity of joints; however, in some patients, symptoms may go unnoticed until adolescence or adulthood. Serum creatine kinase (CK) is usually normal to mildly elevated (<5×).
There have been various changes to the spawn system in the various betas to try to make matches more interesting and more winnable but also without making it such that a team that suffers a major loss of players can still come back. An admin configurable time limit (default 15 minutes) was introduced in beta 5 which remains in the final version. With the time limit, Marines are usually on the attacking side and Kharaa are on the defending side. Failure of the attacking side to win within the time limit results in a victory for the defending side.
Gas phase regioselectivity is calculated to favor 1,5 addition over 1,4 addition by up to 2.9 kcal/mol in activation energy in the gas phase; solvation corrections give the same energy barriers for both regioisomers, explaining the regioisomeric mix that results from DIFO cycloadditions. While the 1,4 isomer is disfavored by its larger dipole moment (all electron-rich substituents on one side), solvation stabilizes it more strongly than the 1,5 isomer, eroding regioselectivity. Experimental studies by Carolyn R. Bertozzi report a nearly 1:1 ratio of regioisomers, confirming the predicted lack of regioselectivity in the addition. Furthermore, nearly all of the distortion energy (92%) arises from the distortion of the 1,3 dipole rather than the cyclooctyne, which has a pre-distorted ground state geometry that increases its reactivity. Fluorination decreases the distortion energy by allowing the transition state to be achieved with a lesser distortion of the 1,3-dipole during a reaction, resulting in a larger dipole angle.
==== Korea ==== The earliest soy sauce brewing in Korea seems to have begun in the era of the Three Kingdoms. Jangdoks used for soy sauce brewing are found in the mural paintings of Anak Tomb No. 3 from the 4th century Goguryeo. In Samguk sagi, a historical record of the Three Kingdoms era, it is written that ganjang (soy sauce) and doenjang (soybean paste), along with meju (soybean block) and jeotgal (salted seafood), were prepared for the wedding ceremony of the King Sinmun in February 683. Sikhwaji, a section from Goryeosa (History of Goryeo), recorded that ganjang and doenjang were included in the relief supplies in 1018, after a Khitan invasion, and in 1052, when a famine occurred. Joseon texts such as Guhwangchwaryo and Jeungbo sallim gyeongje contain the detailed procedures on how to brew good quality ganjang and doenjang. Gyuhap chongseo explains how to pick a date for brewing, what to forbear, and how to keep and preserve ganjang and doenjang.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.